## 1-Benzoyl-4-phenyl-3-thiosemicarbazide: A Versatile Scaffold for Research
1-Benzoyl-4-phenyl-3-thiosemicarbazide is an organic compound with the chemical formula C14H13N3OS. It's a white crystalline solid that's often used as a starting material in the synthesis of other compounds, particularly those with pharmaceutical and medicinal potential.
**Here's why it's important for research:**
* **Versatile Scaffold:** Its structure contains a thiosemicarbazide core, which can be easily modified with various functional groups. This makes it a versatile scaffold for synthesizing a wide range of derivatives with diverse biological activities.
* **Antimicrobial and Antifungal Activities:** Many derivatives of 1-benzoyl-4-phenyl-3-thiosemicarbazide have shown promising activity against bacteria and fungi. These compounds have been investigated for their potential use in treating infections.
* **Antioxidant Properties:** Some derivatives of this compound have demonstrated antioxidant properties, making them potential candidates for protecting against oxidative damage and diseases linked to oxidative stress.
* **Anti-inflammatory Effects:** Several studies have indicated that certain derivatives of 1-benzoyl-4-phenyl-3-thiosemicarbazide exhibit anti-inflammatory properties, potentially useful for treating inflammatory diseases.
* **Anti-Cancer Activities:** Derivatives of this compound have also been investigated for their potential to inhibit the growth of cancer cells. They have shown activity against different types of cancers, including leukemia and breast cancer.
* **Metal Chelation:** The sulfur and nitrogen atoms in the thiosemicarbazide moiety can bind to metal ions, forming stable complexes. This property makes it a promising candidate for developing drugs that target metal-dependent enzymes or for metal detoxification applications.
**Research Focus:**
Current research efforts focus on:
* **Synthesizing new derivatives:** Researchers are exploring different synthetic pathways to create new derivatives with enhanced biological activities and reduced toxicity.
* **Exploring the mechanism of action:** Studies are being conducted to understand how these compounds interact with biological targets and exert their effects.
* **Developing new drug candidates:** Researchers are developing new drug candidates based on the promising activities of these compounds.
**In conclusion:** 1-benzoyl-4-phenyl-3-thiosemicarbazide is a valuable starting material for synthesizing a wide range of derivatives with potential pharmaceutical applications. Its diverse biological activities, including antimicrobial, antioxidant, anti-inflammatory, and anti-cancer effects, make it a promising lead compound for drug development.
1-benzoyl-4-phenyl-3-thiosemicarbazide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 735919 |
CHEMBL ID | 1323332 |
SCHEMBL ID | 13547676 |
MeSH ID | M000603040 |
Synonym |
---|
MLS000121053 |
smr000118439 |
n-[(phenylcarbamothioyl)amino]benzamide |
nsc507159 |
nsc-507159 |
13153-01-0 |
SR-01000635525-1 |
2-benzoyl-n-phenylhydrazinecarbothioamide |
1-benzamido-3-phenylthiourea |
AKOS000568355 |
NCGC00245289-01 |
nsc 507159 |
1-benzoyl-4-phenylthiosemicarbazide |
semicarbazide, 1-benzoyl-4-phenyl-3-thio- |
benzoic acid, 2-((phenylamino)thioxomethyl)hydrazide |
HMS2314C23 |
CCG-45775 |
n-phenyl-2-(phenylcarbonyl)hydrazinecarbothioamide |
STL282678 |
F0331-0131 |
SCHEMBL13547676 |
MS-6803 |
CHEMBL1323332 |
DTXSID50157098 |
mfcd00030080 |
1-benzoyl-4-phenyl-3-thiosemicarbazide |
2-benzoyl-n-phenylhydrazine-1-carbothioamide |
CS-0324558 |
benzoic acid, 2-[(phenylamino)thioxomethyl]hydrazide |
Excerpt | Relevance | Reference |
---|---|---|
" Finally, 20 and 33 were proved to target Ddl in bacterio via intracellular LC-MS dosage of d-Ala, l-Ala and d-Ala-d-Ala." | ( Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio. Ameryckx, A; Frédérick, R; Pochet, L; Saadi, BE; Van Bambeke, F; Wang, G; Wouters, J; Yildiz, E, 2020) | 0.56 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 3.0131 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 6.0546 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 2.8184 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 0.3162 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
P53 | Homo sapiens (human) | Potency | 17.7828 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 25.1189 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 14.0175 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 3.1623 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 1.6360 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 1.2589 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 7.0795 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
protein binding | Glycoprotein hormones alpha chain | Homo sapiens (human) |
follicle-stimulating hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular region | Glycoprotein hormones alpha chain | Homo sapiens (human) |
extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
Golgi lumen | Glycoprotein hormones alpha chain | Homo sapiens (human) |
follicle-stimulating hormone complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
pituitary gonadotropin complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
AID1584836 | Antibacterial activity against Enterococcus faecalis ATCC 29212 after 18 to 24 hrs by microdilution assay | 2018 | European journal of medicinal chemistry, Nov-05, Volume: 159 | 1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio. |
AID1692396 | Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution method | 2020 | European journal of medicinal chemistry, Aug-15, Volume: 200 | Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio. |
AID1584835 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 to 24 hrs by microdilution assay | 2018 | European journal of medicinal chemistry, Nov-05, Volume: 159 | 1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio. |
AID1584832 | Inhibition of Enterococcus faecalis JH2-2 C-terminal 6His-tagged DdlB expressed in Escherichia coli LMG194 assessed as residual activity at 10 uM preincubated for 30 mins followed by substrate addition and measured after 20 mins by Biomol Green reagent as | 2018 | European journal of medicinal chemistry, Nov-05, Volume: 159 | 1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio. |
AID1692394 | Inhibition of recombinant Enterococcus faecalis C-terminal His6-tagged DdlB expressed in Escherichia coli LMG194 assessed as residual activity using D-Ala as substrate at 100 uM preincubated with enzyme for 30 mins followed by substrate addition and measu | 2020 | European journal of medicinal chemistry, Aug-15, Volume: 200 | Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio. |
AID1692397 | Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution method | 2020 | European journal of medicinal chemistry, Aug-15, Volume: 200 | Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 7 (63.64) | 24.3611 |
2020's | 3 (27.27) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.08) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |